| A specific antidote for dabigatran: functional and structural characterization F Schiele, J van Ryn, K Canada, C Newsome, E Sepulveda, J Park, H Nar, ... Blood, The Journal of the American Society of Hematology 121 (18), 3554-3562, 2013 | 765 | 2013 |
| Heparin-induced thrombocytopenia: towards consensus TE Warkentin, BH Chong, A Greinacher Thrombosis and haemostasis 59 (01), 1-7, 1998 | 754 | 1998 |
| Binding kinetics survey of the drugged kinome V Georgi, F Schiele, BT Berger, A Steffen, PA Marin Zapata, H Briem, ... Journal of the American Chemical Society 140 (46), 15774-15782, 2018 | 72 | 2018 |
| Treatment of heparin-induced thrombocytopenia A Greinacher Thrombosis and haemostasis 82 (08), 457-467, 1999 | 71 | 1999 |
| A universal homogeneous assay for high-throughput determination of binding kinetics F Schiele, P Ayaz, A Fernández-Montalván Analytical biochemistry 468, 42-49, 2015 | 70 | 2015 |
| Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis EM Lyle, SD Lewis, DE Lehman, SJ Gardell, SL Motzel, JJ Lynch Jr Thrombosis and haemostasis 79 (03), 656-662, 1998 | 63 | 1998 |
| Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program J Fanikos, D Murwin, F Gruenenfelder, I Tartakovsky, LR França, ... Thrombosis and haemostasis 120 (01), 027-035, 2020 | 48 | 2020 |
| Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection S Halwe, A Kupke, K Vanshylla, F Liberta, H Gruell, M Zehner, C Rohde, ... Viruses 13 (8), 1498, 2021 | 45 | 2021 |
| Characterization of 12 GnRH peptide agonists–a kinetic perspective I Nederpelt, V Georgi, F Schiele, K Nowak‐Reppel, ... British journal of pharmacology 173 (1), 128-141, 2016 | 44 | 2016 |
| An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo F Schiele, J Park, N Redemann, G Luippold, H Nar Journal of Molecular Biology 426 (4), 843-852, 2014 | 44 | 2014 |
| Canada K, Newsome C, Sepulveda E, Park J, et al F Schiele, J Van Ryn A specific antidote for dabigatran: functional and structural …, 2013 | 34 | 2013 |
| Neutralization of both IL-1α/IL-1β plays a major role in suppressing combined cigarette smoke/virus-induced pulmonary inflammation in mice DP Hannes Bucher, Samuel Mang, Martina Keck, Michèl Przibilla, David J Lamb ... Pulmonary Pharmacology & Therapeutics 44, 96-105, 2017 | 30 | 2017 |
| Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease Y Cheng, TR Hall, X Xu, I Yung, D Souza, J Zheng, F Schiele, M Hoffmann, ... EBioMedicine 75, 2022 | 28 | 2022 |
| Management of venous thromboembolism S Haas Hämostaseologie 18 (01), 18-26, 1998 | 20 | 1998 |
| Structure-guided residence time optimization of a dabigatran reversal agent F Schiele, J van Ryn, T Litzenburger, M Ritter, D Seeliger, H Nar MAbs 7 (5), 871-880, 2015 | 11 | 2015 |
| Heparin-induzierte Thrombozytopenie–Pathogenese und Behandlung A Greinacher Hämostaseologie 19 (01), 1-12, 1999 | 10 | 1999 |
| Development of a bispecific antibody-based platform for retargeting of capsid modified AAV vectors J Kuklik, S Michelfelder, F Schiele, S Kreuz, T Lamla, P Müller, JE Park International journal of molecular sciences 22 (15), 8355, 2021 | 9 | 2021 |
| Immunantwort auf rekombinantes Hirudin G Huhle, U Hoffmann, XH Song, DL Heene, J Harenberg Haemostaseologie 19 (01), 50-54, 1999 | 8 | 1999 |
| Rekombinantes Hirudin zur weiteren Antikoagulation bei Patienten mit Heparin-induzierter Thrombozytopenie A Greinacher Hämostaseologie 19 (01), 19-29, 1999 | 6 | 1999 |
| The (fab) ulous destiny of idarucizumab: highlighting its interference with urine protein immunofixation N Gendron, H Flament, E Litvinova, S Ortuno, N Ajzenberg, D Faille TH Open 3 (03), e306-e308, 2019 | 3 | 2019 |
John Edward ParkBoehringer Ingelheim Pharma GmbH & Co KG在 boehringer-ingelheim.com 的电子邮件经过验证
